Abstract
Sentinel lymph node (SLN) imaging and mapping are used to detect nodal metastasis in patients with a number of cancers for staging and prognosis. Macrophages (especially, tumor-associated macrophages or TAMs in the case of cancer), dendritic cells, and reticuloendothelial cells present in SLN express abundant levels of the mannose receptor (MR; CD206). Therefore, several radio-labeled, mannose-containing molecular agents have been designed to target the MR for imaging of SLN using suitable nuclear techniques. Among them, 99mTc-tilmanocept is an FDA-approved imaging agent for SLN, [99mTc(CO)3]DCM20 is an investigational agent for SLN, and [18F]FDM is an investigational agent for other purposes, but has potential for use in SLN mapping. Several other molecular agents that target the MR such as MR nanobody (MMR Nb) and mannose-functionalized liposomes and nanoparticles, are currently under investigation for imaging and drug delivery in cancers and other diseases, but are also being discussed for their potential future use in SLN mapping.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call